Home » Stocks » CRY

CryoLife, Inc. (CRY)

Stock Price: $20.82 USD -0.34 (-1.61%)
Updated November 30, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 809.01M
Revenue (ttm) 255.03M
Net Income (ttm) -13.91M
Shares Out 38.86M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE 714.29
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $20.82
Previous Close $21.16
Change ($) -0.34
Change (%) -1.61%
Day's Open 21.04
Day's Range 20.74 - 21.44
Day's Volume 213,332
52-Week Range 14.66 - 30.57

More Stats

Market Cap 809.01M
Enterprise Value 1.06B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.86M
Float n/a
EPS (basic) -0.37
EPS (diluted) -0.37
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.71M
Short Ratio 17.22
Short % of Float n/a
Beta 1.37
PE Ratio n/a
Forward PE 714.29
P/FCF Ratio n/a
PS Ratio 3.17
PB Ratio 2.52
Revenue 255.03M
Operating Income 4.16M
Net Income -13.91M
Free Cash Flow -42,000
Net Cash -246.93M
Net Cash / Share -6.35
Gross Margin 71.76%
Operating Margin 1.63%
Profit Margin -5.50%
FCF Margin -0.02%
ROA 0.44%
ROE -4.61%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 3
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(32.66% upside)
Current: $20.82
Target: 27.62
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth5.09%38.55%5.17%23.63%0.87%2.75%6.87%10.11%2.56%-
Gross Profit18317312911990.7291.2990.3985.0275.8468.37
Operating Income17.049.317.9713.915.358.8413.8212.6111.649.87
Net Income1.72-2.843.7010.784.017.3216.177.957.373.94
Shares Outstanding37.1236.4133.0131.8627.7427.3826.8926.9727.4427.99
Earnings Per Share0.05-
EPS Growth---65.63%128.57%-44%-56.14%103.57%7.69%85.71%-
Dividend Per Share----
Dividend Growth----0%2.56%134%---
Operating Cash Flow15.839.8810.8019.7211.448.1216.7718.9916.7520.84
Capital Expenditures-8.07-5.79-6.63-6.20-3.49-4.31-4.34-3.07-2.54-2.12
Free Cash Flow7.764.104.1713.527.953.8112.4315.9214.2118.72
Cash & Equivalents34.2942.2440.7557.3443.4239.2642.9918.3322.0240.81
Total Debt23922422671.59------
Net Cash / Debt-205-181-186-14.2443.4239.2642.9918.3322.0240.81
Book Value286275277209155149145128122114
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CryoLife, Inc.
Country United States
Employees 1,200
CEO James Patrick Mackin

Stock Information

Ticker Symbol CRY
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: CRY
IPO Date February 11, 1993


CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.